Avalyn Pharma (NASDAQ:AVLN) Raised to “Strong-Buy” at Jefferies Financial Group

Avalyn Pharma (NASDAQ:AVLN) was upgraded by analysts at Jefferies Financial Group to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

A number of other equities analysts also recently issued reports on the stock. Wall Street Zen raised shares of Avalyn Pharma to a “hold” rating in a research note on Saturday, May 9th. Evercore started coverage on Avalyn Pharma in a research report on Tuesday. They set an “outperform” rating and a $51.00 price target on the stock. Morgan Stanley initiated coverage on Avalyn Pharma in a report on Tuesday. They issued an “overweight” rating and a $53.00 price objective for the company. Finally, Guggenheim started coverage on shares of Avalyn Pharma in a research report on Monday. They issued a “buy” rating and a $80.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. According to MarketBeat, Avalyn Pharma has a consensus rating of “Strong Buy” and an average target price of $59.00.

Avalyn Pharma Trading Down 7.4%

Shares of NASDAQ AVLN opened at $26.70 on Monday. Avalyn Pharma has a 12 month low of $25.05 and a 12 month high of $32.22.

Insider Buying and Selling

In related news, Director Jill Carroll purchased 277,778 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were purchased at an average cost of $18.00 per share, with a total value of $5,000,004.00. Following the transaction, the director directly owned 2,186,562 shares in the company, valued at $39,358,116. This trade represents a 14.55% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Sr One Capital Management, Llc purchased 555,555 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was bought at an average price of $18.00 per share, for a total transaction of $9,999,990.00. Following the purchase, the insider directly owned 2,186,562 shares in the company, valued at $39,358,116. The trade was a 34.06% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.